Global Rosuvastatin Market Size To Worth USD 4.88 Billion by 2033 | CAGR of 3.80%
Category: HealthcareGlobal Rosuvastatin Market Size To Worth USD 4.88 Billion by 2033
According to a research report published by Spherical Insights & Consulting, the Global Rosuvastatin Market Size is Expected to Grow from USD 3.36 Billion in 2023 to USD 4.88 Billion by 2033, at a CAGR of 3.80% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 220 pages with 113 Market data tables and figures & charts from the report on the " Global Rosuvastatin Market Size, Share, and COVID-19 Impact Analysis, By Formulation Type (Injectables, Tablets, and Oral Suspension), By Dose Strength (5mg, 10mg, 20mg, and 40mg), By Indication (Cardiovascular Disease, Atherosclerosis, and Hyperlipidemia), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Detailed Report Description Here: https://www.sphericalinsights.com/reports/rosuvastatin-market
The global rosuvastatin market focuses on developing and distributing drugs to lower cholesterol levels and reduce cardiovascular disease risk. Rosuvastatin, a statin, inhibits an enzyme responsible for cholesterol synthesis, reducing cholesterol levels in the bloodstream. When combined with a healthy diet and exercise, it reduces bad cholesterol and lipid levels, preventing arterial blockages and reducing the risk of cardiovascular diseases like heart disease and stroke. Elevated cholesterol affects 39% of adults, with women having a higher prevalence. In Saudi Arabia, urban and rural areas have higher hyperlipidaemic conditions. Government initiatives like the Therapeutic Lifestyle Changes Program and regulatory bodies like WHO focus on reducing cardiovascular disease mortality. Market growth is driven by government initiatives, drug discovery innovations, pharmaceutical research, and increased awareness of hyperlipidaemic therapeutics. The global demand for rosuvastatin is increasing due to the rise in cardiovascular diseases caused by unhealthy lifestyles, poor food, smoking, and inactivity. This statin, which lowers LDL cholesterol, is particularly beneficial for the geriatric population, who are at higher risk of chronic illnesses. However, patent expiration of rosuvastatin and variations in the reimbursement policy may hinder the growth of the market.
The tablets held the greatest share in 2023 and is predicted to grow at a CAGR of 3.28% during the predicted period.
Based on the type, the global rosuvastatin market is categorized as injectables, tablets, and oral suspension. Among these, the tablets held the greatest share in 2023 and is predicted to grow at a CAGR of 3.28% during the predicted period. Segmental growth of tablets is driven by stability, cost-effectiveness, ease of administration, innovative production methods, patient adherence, self-governance, and preference among children and the elderly for tablets owing to their less invasive and absence of unpleasant taste.
The 10mg and 20mg segment accounted for a remarkable share in 2023 and is anticipated to grow at a substantial CAGR throughout the projected timeframe.
Based on the dose strength, the global rosuvastatin market is categorized as 5mg, 10mg, 20mg, and 40mg. Among these, the 10mg and 20mg segment accounted for a remarkable share in 2023 and is anticipated to grow at a substantial CAGR throughout the projected timeframe. The segmental expansion is driven by factors such as its efficacy, specific genotype-specific dosages, safety-efficacy balance, and potential for future pharmaceutical developments to enhance its adaptability.
The hyperlipidemia segment accounted for the highest share in 2023 and is expected to grow at a substantial CAGR during the forecast period.
Based on the indication, the global rosuvastatin market is categorized as cardiovascular disease, atherosclerosis, and hyperlipidemia. Among these, the hyperlipidemia segment accounted for the highest share in 2023 and is expected to grow at a substantial CAGR during the forecast period. The growth of the segment is attributed to factors such as lack of exercise, obesity, lipid disorders, poor nutrition, preventive healthcare, high saturated fatty acid intake, and insulin resistance.
The hospital pharmacy segment dominated the global rosuvastatin market in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period.
Based on the distribution channel, the global rosuvastatin market is categorized as retail pharmacy, hospital pharmacy, and online pharmacy. Among these, the hospital pharmacy segment dominated the global rosuvastatin market in 2023 and is anticipated to grow at a remarkable CAGR throughout the forecast period. Specialized care, quick access to treatment, drug monitoring services, emergency medication supply, and counselling centers are all contributing to the sector's expansion.
North America is expected to hold the greatest share of the global Rosuvastatin market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global rosuvastatin market over the forecast period. North America's aging population, chronic illnesses, and surgical procedures are increasing demand for medical supplies, which is fueling regional expansion and vital supply.
Asia Pacific is predicted to hold the fastest-growing region of the global rosuvastatin market throughout the estimated period. The market is anticipated to be promoted by government and healthcare measures to address cardiovascular disorders, as well as the region's high population, expanding medical infrastructure, and robust patient base.
Major key players in the global rosuvastatin market are Lunan Pharmaceutical, Teva Pharmaceuticals, Niksan Pharmaceutical, JB Pharma, MSN Laboratories, Glenmark Pharmaceuticals Inc., Nextwell Pharmaceutical, Pfizer, Torrent Pharmaceuticals, Mylan Laboratories, Sandoz, Lupin Pharmaceuticals, Sun Pharmaceuticals, Hikma Pharmaceuticals, Zydus Cadila, Apotex, Kusum Healthcare, and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In January 2025, as per the data published in the Australian Prescriber, it was revealed that from July 2023 to June 2024, Rosuvastatin and Atorvastatin were the most prescribed drugs under the Pharmaceutical Benefits Schedule and Repatriation Pharmaceutical Benefits Scheme, with over 80 people per 1000 taking a standard dose daily.
- In July 2024, Cinfa a European pharmaceutical laboratory launched its novel product Rosvacor (Rosuvastatin) in Qatar. Cinfa's cardiometabolic expansion has reached a significant milestone, offering new therapeutic options for dyslipidemia and cardiovascular disease prevention, with Rosvacor available in doses of 5mg, 10mg, and 20mg.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global rosuvastatin market based on the below-mentioned segments:
Global Rosuvastatin Market, By Formulation Type
- Injectables
- Tablets
- Oral Suspension
Global Rosuvastatin Market, By Dose Strength
- 5mg
- 10mg
- 20mg
- 40mg
Global Rosuvastatin Market, By Indication
- Cardiovascular Diseases
- Atherosclerosis
- Hyperlipidemia
Global Rosuvastatin Market, By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Global Rosuvastatin Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?